![]() | ![]() | ![]() | ![]() | ![]() | |||||||||||||
![]() | |||||||||||||||||
| |||||||||||||||||
| |||||||||||||||||
Zestra™ for Women Increases Sexual Pleasure In Women with FSADThe title of the presentation was: RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, CROSSOVER DESIGN PILOT TRIAL OF THE EFFICACY AND SAFETY OF ZESTRA™ FOR WOMEN IN WOMEN WITH FEMALE SEXUAL AROUSAL DISORDER. Zestra™ for Women was studied in 10 women with Female Sexual Arousal Disorder (FSAD), in at-home use. Zestra™ for Women showed statistically significant (P < .05) benefits over placebo in desire, sexual pleasure, and arousal. "These results are impressive considering the size of the study," said Dr. Ferguson, a prominent researcher in sexual dysfunction studies and consultant for QualiLife who managed the study. "When the results from the second treatment period are analyzed, the endpoints for orgasm may also become significant. I look forward to confirming these results in a large multi-center trial." Other authors included Christopher Steidle, MD, Gita Singh, MD, Steven Alexander, MD, PhD, and Kathy Weihmiller, RN, MSN. For complete study details and results, and a copy of the slide presentation from the conference, please visit www.zestra-women.com
About QualiLife Pharmaceuticals, Inc. (Women's Consumer Product Division) Industry: Health, Pharmaceutical Keywords: South Carolina, Delaware |
|
![]() | |||||
| |||||